Outshine the giants: these 24 early-stage AI stocks could fund your retirement.
To own Veeva, you need to believe its life sciences cloud and AI roadmap can keep attracting large pharma customers despite rising competition and deal-cycle uncertainty. Vipin Kondath’s appointment as principal accounting officer looks incremental for that thesis, reinforcing continuity in financial reporting rather than altering near term catalysts or the biggest risks around AI adoption, competition from larger software vendors, and spending pressure at pharma customers.
The recent launch of Veeva AI Agents across Vault CRM and PromoMats feels far more central to the story, because it directly relates to whether customers embrace new AI workflows or show resistance and fatigue. If AI-driven products gain traction across clinical, regulatory, safety, quality, and commercial use cases in 2026, that could be a key driver of higher product stickiness and suite adoption, but if uptake is slow it could also highlight...
Read the full narrative on Veeva Systems (it's free!)
Veeva Systems' narrative projects $4.3 billion revenue and $1.3 billion earnings by 2028.
Uncover how Veeva Systems' forecasts yield a $312.18 fair value, a 41% upside to its current price.
Six members of the Simply Wall St Community currently see Veeva’s fair value between US$230 and about US$312 per share, with some estimates well above the current price. You can weigh those personal models against the risk that slow AI adoption or customer hesitation could limit the payoff from Veeva’s recent AI Agent launches and affect future operating performance.
Explore 6 other fair value estimates on Veeva Systems - why the stock might be worth as much as 41% more than the current price!
Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.
Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com